• ECGI Holdings is targeting a share of the growing luxury goods market by designing, manufacturing, and selling luxury equestrian apparel and equipment through its subsidiary Pacific Saddlery
• The company sees the utilization of smaller focused markets as a proven entrance pathway to much larger general luxury markets
• Bain & Company valued the global luxury goods market at €362 billion ($395.4 billion) in 2023 and expects this market to grow to between €540 billion ($589.8 billion) and €580 billion ($633.5 billion) by 2030
• ECGI Holdings and Pacific Saddlery are using celebrated brands like Hermès, Gucci, and Ralph Lauren as a template for what’s possible in the luxury market
• Throughout their respective histories, celebrated luxury brands have continuously incorporated equestrian elements into their designs to capitalize on the timelessness, prestige, and positive connotation attached to horses

ECGI Holdings (OTC: ECGI), a diversified holding company focused on luxury fashion, equestrian, and viticulture markets, recognizes that a marginal share of a globally large market would translate to more revenue annually than even a big share of a small market, and sees smaller focused markets as a proven entrance pathway to much larger general luxury markets.

To put the figures and logic into perspective, Bain & Company published its annual Luxury Goods Worldwide Market Study, which noted that the personal luxury goods segment of the overall luxury market recorded €362 billion ($395.4 billion) in spending in 2023. This represented a 4% increase over 2022 figures (at January 2024 exchange rates) or an 8% increase (at constant exchange rates) (https://ibn.fm/vxiS2).

Anchoring this increase was the growth in all personal luxury goods categories, including accessories, apparel, beauty, watches, and jewelry. Looking ahead, Bain & Company forecasts moderate growth in the personal luxury goods segment in 2024, ranging between 1% and 4%. Beyond 2024, the analysis report projects that the market will post annual growth rates of 5% to 7%, reaching €540 billion ($589.8 billion) to €580 billion ($633.5 billion) by 2030. (For ECGI Holdings, therefore, a marginal share of this market would translate to millions of dollars in revenue through 2030.)

With the study urging luxury brands to focus on creativity and innovation “to enhance relevance to consumers, with the ultimate goal of continuing to expand their client bases while cultivating brand lovers,” fashion houses are expected to continue incorporating timeless trends and elements that have endured seasons and events. And when it comes to timelessness, few things come close to the allure and symbolic power of the upscale equestrian market.

For ages, horses have represented royalty, nobility, and grace. Fast forward to today, high-end fashion brands like Hermès (OTC: HESAF), Ralph Lauren (NYSE: RL), and Gucci, which is part of Kering Group (OTC: PPRUF), celebrated designers like Stella McCartney, and mainstream fashion houses have incorporated equestrian aesthetics and motifs into their creations. ECGI Holdings, too, has jumped on this bandwagon through Pacific Saddlery, its subsidiary and leading manufacturer and retailer of equestrian apparel, tack, equipment, and accessories.

These brands have converted what would otherwise be considered ordinary riding attire and accessories into symbols of luxury and sophistication, targeting affluent consumers who invest in high-end products and services related to horse care and horse riding. By embracing equestrian chic, these fashion houses have continued to move the needle in the growing luxury equestrian market, a niche segment of the luxury goods and luxury markets.

Valued at tens of billions of dollars, the luxury equestrian market is segmented into two: the luxury equestrian apparel segment, which covers the design, production, and sale of high-end riding gear like helmets, boots, jackets, and breaches, and the luxury equestrian tack and equipment segment, which comprises brands that manufacture premium saddles, bridles, and tack.

For its part, Pacific Saddlery creates products for both segments. Having initially focused on the equestrian tack and equipment segment – a focus that saw it manufacture and sell bridles, reins, and martingales under its celebrated Allon brand – Pacific Saddlery is preparing to launch a new collection of equestrian apparel under this brand (https://ibn.fm/QJb9S).

Through this launch, Pacific Saddlery will follow a path trodden by Hermès before it. A French luxury design house, Hermès was established in 1837 as an artisanal workshop that primarily crafted harnesses. It then went on to introduce made-to-measure saddles, beginning in the 1880s, before introducing additional products. Today, Hermès is a celebrated brand that makes products across various métiers that contributed to consolidated revenue in the first half of 2024 of €7.5 billion ($8.19 billion) (https://ibn.fm/WZINc).

Pacific Saddlery and ECGI Holdings are nonetheless not out to replicate Hermès’ and other established luxury brands’ models exactly; rather, they wish to use such brands as an inspiration of what is possible if they adopt and maintain the required level of creativity, innovation, and strategic decision-making. This approach, ECGI Holdings hopes, will help it expand its customer base and, as a result, grow its market share in the luxury goods and luxury equestrian markets, leading to significant revenues.

For more information, visit the company’s website at www.ECGIHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to ECGI are available in the company’s newsroom at https://ibn.fm/ECGI

• Clene has conducted five Phase 2 clinical trials, three with long-term extensions, and three expanded access programs (with additional studies ongoing) to evaluate the safety and efficacy of CNM-Au8
• The global ALS treatment market is poised for growth, driven by an aging population and limited current treatment options
• CNM-Au8 works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health, and is at a deficit in neurodegenerative diseases

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). In the recent Emerging Growth Conference 73 on July 17-18, 2024, CEO Rob Etherington and CFO Morgan Brown presented new findings and information about the company and its lead drug candidate, pertinent to current and potential investors.

In the opening of the presentation, Etherington explained that mitochondria play a vital role in cellular metabolism and energy production, and that impaired mitochondrial function is a significant issue in neurodegenerative diseases. Clene’s lead agent, CNM-Au8(R), works by improving cellular energy production and utilization via the nicotinamide adenine dinucleotide (NAD+) pathway, which is crucial for maintaining neuronal health. By addressing mitochondrial dysfunction, CNM-Au8 provides neuroprotection and promotes remyelination, potentially altering the course of debilitating neurodegenerative diseases. This innovative approach aims to restore and protect neurological function (https://ibn.fm/j7gYH).

CNM-Au8 is being investigated to treat neurodegenerative diseases in clinical studies and comprehensive compassionate use programs in ALS, MS, and even one study in Parkinson’s Disease, Etherington explained.

The Clene CEO also highlighted the strong safety profile of CNM-Au8, with over 650 years of cumulative subject exposure and no serious adverse events linked to the drug. Extensive clinical trials have been conducted to evaluate its safety and efficacy. Phase 2 trials for ALS have shown improved survival rates and delayed clinical worsening. Additionally, significant improvements in biomarkers and functional outcomes were observed.

The company is now preparing for Phase 3 studies for both ALS and MS, while seeking feedback from the Food and Drug Administration on a potential pathway for accelerated approval for CNM-Au8.

The global ALS treatment market is expected to grow significantly due to the increasing prevalence of the disease among the aging population. Grand View Research reports that the market is anticipated to reach $885.5 million by 2026, but the growth may be hindered by the high costs associated with ALS treatments (https://ibn.fm/cprPz).

According to Etherington, ALS is more common than thought, and treatment options are severely limited both in the United States and worldwide, making the potential impact of CNM-Au8 even more significant. Department of Health Resources & Services data indicate that the estimated prevalence of ASL in the U.S. was 5.2 per 100,000 people in 2015.

Etherington further noted that CNM-Au8’s ability to penetrate the blood-brain barrier and its neuroprotective properties make it a promising candidate not only for ALS and MS but also for other neurodegenerative diseases.

As the company continues to make significant strides in addressing critical unmet needs in the market, its innovative approach, robust intellectual property portfolio, and promising clinical data position Clene as a leading entity in the field of neurodegenerative disease treatment.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• Domestic violence worldwide is fostering a concerted response by criminal justice officials and legislators upset by the deadly fallout of offenders who violate court-ordered protective measures for victims
• Tennessee recently passed a statewide law establishing specific targets for electronic monitoring of offenders via GPS and communication with victims, creating clear and timely awareness of situations in which offenders are in proximity to victims
• Electronic monitoring technology innovator SuperCom Ltd. has developed a suite of hardware, connectivity, and software components designed to target the market for monitoring domestic violence offenders and alerting their victims to dangers
• SuperCom recently reported over $11 million in new revenue for the company from European clients, placed within three months

The severe consequences of domestic violence incidents are driving the monitoring of offenders’ whereabouts via electronic GPS-enabled technologies.

Tennessee enacted a law last month described as the first in the nation to codify measures statewide requiring electronic GPS monitoring (“EM”) for people arrested for stalking, aggravated stalking or especially aggravated stalking. The law also encompasses offenses related to assault, kidnapping, or rape, targeting a specific person, and allowing victims of such crimes to be notified through a phone app when offenders, in their cases, move close to their location.

“Those critical seconds of giving a victim the ability to know that someone is outside or near them puts them in a different space and gives them more tools”, said Alex Youn, a relative of a Tennessee mother-daughter duo killed in an incident that inspired passage of the law (https://ibn.fm/hHL3G).

EM solutions developer SuperCom (NASDAQ: SPCB) is advancing its technological innovations as a means of combatting the rising incidence of domestic partner stalking and attacks, not only in the United States but around the world. “People have been trying to do electronic monitoring for over 30 years, but many of the times they ran into technological hurdles,” company President and CEO Ordan Trabelsi said during a Your Advantage Play podcast interview (https://ibn.fm/T0zX5). “With every project, we’re able to be one step ahead of the curve.”

SuperCom’s PureSecurity suite of hardware, connectivity, and software components is emerging as a powerful tool for governments and private organization clients. The company recently celebrated $11 million in new European orders within three months (https://ibn.fm/Vu6XB). SuperCom’s technology is primarily designed for offender monitoring, ensuring that individuals under legal restrictions are accurately tracked, while also being adaptable for related needs such as tracking Alzheimer’s patients prone to wandering. The company also offers identification solutions, such as electronic passports, biometric visas, driver licenses, and voter authentication capabilities. Moreover, the primary focus is on the criminal offender monitoring space. It is a niche sector with relatively few competitors, and SuperCom sees it as the sector with the greatest opportunities.

Statistics generated by the Maricopa County Attorney’s Office in Arizona indicate that, nationwide, people are physically abused by an intimate partner at a rate of 20 per minute, amounting to millions of incidents per year. The report indicates that about 100 fatalities in the state each year are due to domestic violence, including not only the partner targeted but Good Samaritan bystanders and first responders. The report also points to a 2017 study by the Centers for Disease Control and Prevention, estimating that almost 40% of people in Arizona had been subject to some form of domestic abuse (https://ibn.fm/KAqXr).

Tennessee, where the landmark EM protection bill was passed into law last month, is the seventh-most deadly state for incidents of men attacking women, according to a domestic shelter executive. Thirteen other states have also begun using GPS tracking to limit the risks associated with domestic violence offenders, revealing the growing market for products such as SuperCom’s platform (https://ibn.fm/gGYnC).

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• U.S. Patent No. 12,042,482 specifically addresses traumatic brain injury (“TBI”) treatment with buntanetap, enhancing Annovis Bio’s portfolio that includes various patents and applications for using buntanetap in treating both acute and chronic neurodegenerative diseases and mental illnesses
• Buntanetap targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins such as amyloid beta, tau, alpha-synuclein, and TDP43
• TBI is one of the major causes of death and disability in the US with annual death rate exceeding 70,000

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, announced the issuance of a U.S. patent for treating traumatic brain injury (“TBI”) with its lead drug candidate, buntanetap. Initially filed in 2016, the patent covered treatments for various nerve injuries, including TBI, stroke, and spinal cord injuries, but required division into individual patents by the USPTO. Now, U.S. Patent No. 12,042,482, which specifically addresses the treatment of TBI and nerve injury with buntanetap, is successfully added in Annovis Bio’s diverse portfolio covering treatments for multiple acute and chronic neurodegenerative diseases and mental illnesses (https://ibn.fm/tU6FR).

Buntanetap (formerly Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins such as amyloid beta, tau, alpha-synuclein, and TDP43; by inhibiting their translation the drug improves synaptic transmission, axonal transport, reduces neuroinflammation, and protects nerve cells from dying. Unlike monoclonal antibody therapies, buntanetap is an orally available small molecule that inhibits multiple neurotoxic proteins simultaneously, making it a promising solution for neurodegenerative diseases.

Maria Maccecchini, Ph.D., the company’s Founder, President, and CEO, highlighted the importance of this milestone, noting the drug’s demonstrated efficacy in preventing nerve cell death in preclinical TBI and stroke models. “We are thrilled to achieve this significant milestone for buntanetap. Nerve cell death is a common underlying factor in many brain conditions, beyond just Alzheimer’s and Parkinson’s,” Maccecchini said. “Our preclinical studies in TBI and stroke animal models have demonstrated buntanetap’s efficacy in preventing cell death and loss of function, and it is our duty to explore its potential benefits for victims of brain trauma, a prevalent issue in the U.S.”

In a recent Phase II/III Alzheimer’s study, buntanetap demonstrated statistically significant efficacy, with early Alzheimer’s patients showing substantial improvement in cognitive scores and reduced plasma Tau protein levels. Similarly, findings from the Phase III study in Parkinson’s disease (“PD”) patients indicate promising results in several disease subpopulations, where the drug improved PD-related functions and halted cognitive decline.

Annovis has a unique market position as the only company developing a drug that inhibits multiple neurotoxic proteins for both Alzheimer’s disease and Parkinson’s disease, distinguishing it from other industry players. The company’s commitment is evident in its approach to restoring brain function and improving patient outcomes, highlighting its dedication to pioneering effective therapies in this critical field.

For more information, visit the company’s website at www.AnnovisBio.com, and social channels
LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

CBDC Cruises offers a once-in-a-lifetime experience with its ‘Summit on the Seas’ to C-level executives, professionals, enthusiasts, and members of the Crypto, DeFi, and Blockchain community.  Attendees can enjoy top-notch amenities and a luxury experience as the cruise sets sail from Fort Lauderdale on November 16, 2024. Be a part of first-class networking, discussions, explorations, and collaborations as executives, enthusiasts, and families, all will sail aboard for the event. 

Cabins and reservations are limited. Apart from business, education, and networking, attendees can relax and enjoy drinks and Round Robin dinners. The cruise offers world-class entertainment, visits to scenic ports, and, most importantly, an amicable environment to work and connect with like-minded individuals. Attendees can immerse themselves in the unforgettable experience of a cruise curated only for the attendees of the blockchain conference.

Registrations are open for those interested in hosting speaker sessions. Industry leaders and stalwarts of blockchain technology will preside over speaker sessions. The discussions and interactions with the immersive audience of executives, creative minds, newcomers, and investors will offer insights into the latest trends, challenges, and solutions in the crypto, blockchain, and DeFi sectors. 

The speaker session agenda includes topics like blockchain, DeFi, crypto, Web3, IoT, fintech, AI, digital gaming, and other issues of relevance for future technologies. Attendees can also attend the workshops to gain expertise and sharpen their skills to stay ahead in the competition. Apart from the above, the event will host CBDC hackathons, workshops, and service events dedicated to a cleaner earth and ocean. 

Newbies and veterans can express their views at the discussion panels, speaker sessions, and the leadership seminars. Registrations are open for those interested to apply for hosting speaker sessions. Industry leaders and stalwarts of the Blockchain technology will preside over speaker sessions. They will navigate through the entire spectrum of future technologies. The discussions and interactions with the immersive audience of executives, creative minds, newcomers, and investors, will offer insights into the latest trends, challenges, and solution.

Professionals with families and children can embark on this conference cruise experience with ease as daily childcare is available.

For those interested in speaking at the event but unable to secure a cabin due to limited availability, a virtual participation option is available. To arrange this or for further inquiries, please contact hello@bli.tools.

To learn more, please visit https://cbdccruise.com

Cannabis growers, traders, license holders, physicians, patients, regulatory authorities, capital investors, professionals, and enthusiasts are invited to attend the CannaCon Cleveland Conference at the Huntington Convention Center, Cleveland, on October 3-4, 2024. The venue of the event, the Huntington Convention Center is situated in the heart of downtown Cleveland, near the legendary Rock & Roll Hall of Fame and the International Women’s Air & Space Museum, among others.

The CannaCon event offers a robust platform for the local cannabis community, with two full days of innovation, learning, networking, and collaboration. Exhibitors from around the world will be pitching their latest products and services to a crowd of established investors and business experts in the cannabis industry. Newbies and startups gain important visibility by showcasing their unique products and services for the right target audience.

Local businesses will be there to connect with cannabis leaders and investors. Attendees will witness an impressive lineup of industry leaders presiding as guest speakers. They will share invaluable insights about current industry trends and discuss the critical issues of current cannabis trade.

These leaders will cover a number of engaging topics, offering the best path forward to the cannabis community. From harvest quality to understanding the best practices to comply with rules and regulations, attendees can get answers to their queries regarding cannabis cultivation and trade in Cleveland.

Several plush accommodations are available near the Huntington Convention Center for the attendees. CannaCon serves as a business as well as an educational experience. Attendees will discover a wealth of information, products, and valuable connections, from cultivation supplies, cannabis innovations, discoveries in genetics,  and a wide range of vendor retail displays, to important scientific, legal, financial, and marketing ideas. Don’t miss out on this rich event.

To learn more, please visit https://ibn.fm/zg7DP

Join the crypto saga as Crypto Fest returns with its 6th edition, bringing together the dynamic African crypto and blockchain community in the picturesque city of Cape Town, South Africa on October 10-12th, 2024. This year Crypto Fest 2024 expands over three days with the main event on the 11 October taking place at the iconic DHL Stadium, home to the FIFA World Cup in 2010 a centrally located iconic landmark with excellent facilities, accessibility, and a rich legacy.

Bitcoin Events has been the proud host of Crypto Fest for the last five years, and has witnessed thousands of attendees from 120 countries, 5 events, and 160+ speakers thus far. The event brings together executives, professionals, innovators and brands from the realms of cryptocurrency, blockchain, NFTs, the Metaverse, Web3, and Decentralized Finance (DeFi).

Crypto Fest 2024 offers a phenomenal networking platform where 500+ attendees can participate in well-equipped workshops, informative sessions, exhibitions of the latest products and technologies, and other networking events. World leaders make their presence felt at the Crypto Fest event, offering invaluable ideas and expertise for the best way ahead into the world of cryptocurrencies and blockchain technology.

On Day 1, the Crypto Fest 2024 commences with a great city tour, while allowing attendees to forge connections and cultivate meaningful relationships amidst scenic landscapes. Day 2 will feature 15+ sessions hosted by international and local speakers. These global leaders will offer insights and strategies on the latest trends and emerging technologies. On day 3, the participants can relax and unwind with a captivating Cape Town Winelands Tour.

Participants at Crypto Fest can explore and learn the intricacies of finance and technology to more effectively navigate the crypto space. Attendees can participate in numerous events, winning prizes and taking advantage of freebies, while learning how to take their experience to the next level.

To learn more, please visit https://ibn.fm/Fcs1V

Businesses, entrepreneurs, investors, educators, patients, advocates, and consumers are invited to attend the NECANN Michigan Cannabis Convention on September 20-21, 2024, in Grand Rapids. NECANN events are organized to meet the needs and provide collaborative opportunities for the local cannabis community. One of the biggest cannabis conventions in the country, NECANN events witness some of the most eminent dignitaries of the cannabis spectrum gracing the event floor.

Instead of hosting generic cannabis conventions, NECANN took a customized approach. As every region has its challenges, NECANN understands the specific requirements relevant to the area. They collaborate with local traders, growers, investors, sponsors, and industries, so that the regional cannabis community benefits as a whole and enjoys a higher ROI. Operational since 2014, the NECANN team ensures all industry leaders and companies attend the event, expanding business opportunities for local cannabis traders.

Investors can discover fresh and innovative talent at the event. Budding companies can showcase their products and services at the exhibition booths. Investors and cannabis traders can have one-on-one conversations and develop business ties. Attendees can gain insights into the latest trends, and get know-how on the latest industry products and services at the NECANN event.

Top industry leaders conduct speaker sessions where they will share their invaluable expertise. Attendees can gain immense knowledge about current cannabis markets, and can learn about the tips, resources, and tools required to design winning marketing strategies in a competitive cannabis landscape. Experts presiding over the discussion panels will discuss new trends and techniques for the cannabis market to help businesses drive higher ROI.

To know more, please visit https://ibn.fm/JlL43

• Survey indicates sizable proportion of older adult population copes with healthcare costs by skipping treatments, cutting back on basic and essential needs
• Astiva Health is keenly aware of problems faced by underserved senior population
• The company strives to bridge healthcare gaps through proactive, culturally responsive solutions

As growing numbers of the U.S. population reach age 65, the challenge of adequate healthcare becomes even more critical. In fact, a West Health-Gallup survey reports that some elderly are forgoing needed care because of healthcare costs (https://ibn.fm/pJGqA). Astiva Health, a dynamic and innovative Medicare Advantage Prescription Drug (“MAPD”) health plan, is on a mission to meet the challenges faced by underserved aging populations by reshaping the landscape of personalized and comprehensive healthcare.

“The West Health-Gallup survey shows that a sizable proportion of the older adult population copes with healthcare costs by skipping treatments and cutting back on basic and essential needs,” the Gallup report stated. “The avoidance of vital medical care could compound negative health outcomes now and in the future.

“Twelve percent of those 65 and older — which represents approximately 6.5 million people — say they or a member of their household had a health problem in the last year that they did not seek treatment for due to cost,” the article continued. “Eleven percent of Americans in this age group — six million people — report that they or a family member skipped prescribed pills to save money.”

Astiva Health is keenly aware of the problems faced by the underserved senior population and has set out to offer solutions carefully designed to serve specific groups. Currently focused on addressing the healthcare needs of individuals across Southern California, the company serves Medicare enrollees in California, including Orange, San Diego, Los Angeles, Riverside, and San Bernardino, offering full medical, drug, and supplemental benefits.

Recognizing the critical need for healthcare solutions designed to meet specific needs, Astiva Health is initially focused on serving the Asian American and Pacific Islander populations, which positions the company in a critical and expanding market segment that offers substantial growth potential. The company recognizes the diverse needs within its served communities and strives to bridge healthcare gaps through proactive and culturally responsive solutions.

Additionally, Astiva Health focuses on supporting its senior members, many of whom are struggling with daily needs due to the rising cost of living while receiving a modest monthly income. Astiva addresses these challenges by maximizing supplemental benefits that are most practical for their members, such as grocery and transportation assistance, vision, hearing, and dental care. The company also provides benefits designed to keep seniors engaged, such as gym and sports club memberships, and out-of-country travel health insurance.

“Astiva Health cares about its members and works to establish lifelong relationships with them by providing a tailored approach to healthcare, offering multilingual solutions for customer service, marketing materials, and educational resources,” the company states. “Health is an essential key to living a good life, and Astiva Health makes it a priority to help members love the life they live.”

That concept is captured in the company’s mission, which is to deliver an unparalleled level of quality care to its members and offer Medicare Advantage plans that provide lower costs and additional benefits beyond original Medicare coverage. In fact, Astiva Health works closely with a variety of partners that offer services such as transportation, vision, dental, hearing, fitness, telehealth, acupuncture, and chiropractic. Astiva’s forward-thinking strategy not only fulfills a critical societal need but also ensures sustainable growth and transformative impact across diverse communities.

Astiva Health is committed to being a leader in the Medicare Advantage space. The company will reach that objective by offering community-based health plans focused on serving individual member needs and tailored comprehensive benefit packages that best support its local, underserved member population.

For more information, visit the company’s website at www.AstivaHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva

• Lexaria, a global innovator in drug delivery platforms, is exploring alternatives to traditional diabetes and obesity management through its patented DehydraTECH(TM) technology to potentially enhance oral ingestion vs. injection treatment of GLP-1 drugs
• The company has made significant strides pairing their bioavailability enhancing DehydraTECH with glucagon-like peptide-1 (“GLP-1”) drugs used for treatment of diabetes and obesity
• Projections are that by 2030 over 54.9 of Americans could have diabetes, and that by 2045 one in eight adults globally will be living with the condition

According to the International Diabetes Federation Diabetes Atlas of 2021, 10.5% of adults aged between 20 and 79 globally have diabetes. In addition, almost half of them are unaware that they are living with the condition. The Federation further projects that by 2045, one in eight adults in the world will be living with diabetes. This will represent approximately 783 million people, an increase of 46% from the current numbers (https://ibn.fm/yow5m).

The figures in the United States are just as startling, with 38.4 million people of all ages, or 11.6% of the country’s population having diabetes, according to the Centers for Disease Control (“CDC”) (https://ibn.fm/hXwVn). Also, a Population Health Management report shows estimates that, by 2030, over 54.9 million Americans will have diabetes, representing a 54% increase between 2015 and 2030 (https://ibn.fm/GGPTB). These statistics have prompted organizations and societies to initiate and sustain conversations around diabetes and its management.

They have also pushed organizations to explore ways to manage the condition better, and one that has stood out is Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms. Lexaria looks to offer a better alternative to diabetes management and treatment through its patented DehydraTECH(TM) technology. Testing conducted since 2016, has demonstrated the technology’s ability to increase bio-absorption. It has even evidenced an ability to deliver some drugs more effectively across the blood-brain barrier, with its range of applications scaling across bioactive molecules, oral cannabinoids, and other active pharmaceutical ingredients (“APIs”).

Lexaria has recently made strides with glucagon-like peptide-1 (“GLP-1”) studies. It has reported positive interim results from an animal study on diabetes. This milestone best showcases the potential of its patented technology in not only addressing diabetes and obesity. In the last month, the company announced the dosing completion of its human pilot study #2, GLP-1-H24-2, which sought to explore effective oral delivery of GLP-1 drugs. Some evaluated aspects included side effects, blood levels of semaglutide, the GLP-1 drug used in the study, and tolerability. The study also measured blood glucose and insulin levels, ultimately serving as an indicator in the potential treatment of diabetes and weight loss (https://ibn.fm/dJuuy).

GLP-1 drugs have been lauded for their potential to treat diabetes. However, when consumed orally, the stomach’s acidic environment seriously degrades its bioavailability, resulting in meager blood absorption rates of less than 1%, which is far from ideal. This has restricted their administration to painful injections, which can be a deterrent to some people.

“Most GLP-1 drugs sold today are administered by painful and expensive injection devices. More effective and tolerable oral delivery of GLP-1 drugs could be extremely valuable to patients and to industry,” noted Chris Bunka, Lexaria’s CEO (https://ibn.fm/RepgJ).

With Lexaria’s DehydraTECH technology, increased bioavailability has been evidenced, bringing the company closer to offering a viable alternative to injectable delivery of GLP-1 drugs. In addition, the studies conducted so far have shown better tolerability of the GLP-1 drugs used, mainly Rybelsus(R), further pointing to the technology’s superiority and highlighting its potential in treating weight loss and diabetes.

Lexaria recognizes a market opportunity with its technology. It also recognizes a growing problem that needs to be addressed sooner rather than later. For a market valued at $79.3 billion in 2023, the company looks to create significant additional value for its shareholders (https://ibn.fm/OfKl0). As it continues with its GLP-1 studies, its management is optimistic about their outcome.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX